Corium

Executive Summary

Corium is a commercial-stage biopharmaceutical company headquartered in Grand Rapids, Michigan, that focuses on the development and commercialization of novel neuroscience therapies. Founded in 1997, the company specializes in drug delivery technologies and generic drugs, aiming to provide clinicians with differentiated treatment options for patients with central nervous system (CNS) disorders and their caregivers. By leveraging proprietary drug delivery platforms, Corium enhances the efficacy, safety, and convenience of existing and new molecular entities, addressing unmet needs in areas such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. Despite its established commercial presence and long history in the pharmaceutical industry, the company remains privately held, with limited public financial disclosures. Its competitive edge lies in combining neuroscience expertise with advanced transdermal and oral drug delivery systems, enabling improved patient compliance and therapeutic outcomes. The company's product portfolio includes both branded and generic medications, with a focus on expanding its neuroscience pipeline through internal research and potential partnerships. While Corium has a track record of bringing products to market, its future growth depends on successful regulatory approvals, clinical trial advancements, and strategic collaborations that broaden its reach in the CNS therapeutic area. With a strong foundation in drug delivery and a commitment to neuroscience innovation, Corium is positioned to capitalize on the growing demand for effective CNS treatments, particularly as the global population ages and neurological disorders become more prevalent.

Upcoming Catalysts (preview)

• Q4 2026FDA approval of a new transdermal patch for Alzheimer's disease70% success
• Q3 2026Announcement of partnership with a major pharma for Parkinson's treatment50% success
• Q2 2027Phase 3 results for a novel oral formulation of an existing CNS drug60% success